Seizure Clusters & Rescue Therapy
Seizure clusters, also termed acute repetitive seizures, represent a pattern of increased seizure activity that deviates from a patient’s typical seizure frequency and constitutes a medical urgency requiring prompt intervention. Many people with epilepsy experience seizure patterns that follow an infradian (multiday) cycle, with clusters occurring on a regular or semiregular basis. Rescue therapies — rapid-acting benzodiazepines administered via non-intravenous routes — allow patients and caregivers to abort seizure clusters in the community setting before they escalate to status epilepticus. The availability of FDA-approved intranasal and buccal formulations has expanded access to effective, socially acceptable rescue options beyond rectal diazepam.
Bottom Line
- Definition: Seizure clusters are multiple seizures occurring over a short period (typically 24 hours to a few days) that represent a departure from the patient’s baseline seizure pattern; they must be distinguished from normal seizure pattern variability
- Prevalence: An estimated 20–30% of patients with epilepsy experience seizure clusters; they are associated with increased emergency department visits, hospitalizations, and risk of status epilepticus
- Risk factors: ASM nonadherence, intercurrent illness, sleep deprivation, alcohol or illicit drug use, menstrual cycling (catamenial epilepsy), emotional stress; preexisting epilepsy with drug resistance is the strongest risk factor
- Rescue medications: Three FDA-approved outpatient seizure-cluster (acute repetitive seizure) formulations: rectal diazepam (Diastat), intranasal diazepam (Valtoco), and intranasal midazolam (Nayzilam); a separate IM midazolam autoinjector (Seizalam) is FDA-approved for status epilepticus, not for outpatient cluster rescue
- Seizure action plans: Every patient with epilepsy at risk for clusters should have a written, individualized seizure action plan that specifies when to administer rescue medication, correct dosing, and when to call emergency services
- Cluster as first seizure: When seizure clusters are the presenting seizure, the patient is at substantially increased risk of death over subsequent years
Definition and Pathophysiology
What Constitutes a Seizure Cluster?
There is no universally accepted quantitative definition of a seizure cluster. The clinical determination involves recognizing a pattern of seizure activity that is clearly beyond the patient’s typical baseline. Practical working definitions include:
- Clinical definition: Two or more seizures within 24 hours for patients who typically have ≤1 seizure per day, or three or more seizures within 24 hours for patients with higher baseline frequency
- Patient-specific definition: Any increase in seizure frequency, severity, or pattern that represents a clear departure from the individual’s established seizure pattern, as determined by the patient, caregiver, or clinician
- Qualitative factors: Increased seizure severity, failure to recover fully between seizures, occurrence of seizure types not previously experienced, or decreasing intervals between seizures within the cluster
Seizure Cycling Patterns
Many people with epilepsy experience a pattern in which multiple seizures occur on an infradian (multiday or multidien) cycle, followed by many days without seizures or with only random single seizures. This phenomenon has been documented through electronic seizure diaries and wearable devices. The cyclical nature of epilepsy has important implications:
- Infradian cycles: Seizure clustering on a multiday cycle (e.g., monthly) occurs in a large percentage of patients; this must be distinguished from an abnormal seizure cluster requiring rescue intervention
- Circadian patterns: Some patients cluster seizures at specific times of day (e.g., nocturnal clusters in frontal lobe epilepsy, awakening clusters in juvenile myoclonic epilepsy)
- Catamenial patterns: Women with epilepsy may experience perimenstrual (days –3 to +3 of menses), periovulatory (days 10–13), or luteal phase clustering related to fluctuations in estrogen and progesterone
Distinguishing Abnormal Clusters from Normal Seizure Variability
- Maintaining a long-term seizure calendar (diary, smartphone app, or wearable device data) is invaluable for establishing the patient’s baseline pattern
- Factors suggesting an abnormal cluster requiring intervention: seizures are more frequent or severe than the typical pattern; failure to recover awareness between seizures; seizures are occurring in response to an identifiable trigger (illness, missed medications); intervals between seizures are decreasing
- Factors suggesting normal pattern variability: Number and severity of seizures are within the range of the patient’s established cyclical pattern; patient recovers normally between seizures; no identifiable trigger
- When in doubt, err on the side of treating — the consequences of untreated escalation (status epilepticus) are far more serious than the adverse effects of a single dose of benzodiazepine
Risk Factors for Seizure Clustering
Common Triggers
| Trigger Category | Specific Triggers | Mechanism / Clinical Notes |
|---|---|---|
| Medication-related | ASM nonadherence, missed doses, drug interactions reducing ASM levels, switching to generic formulations | Most common identifiable trigger; even a single missed dose of a short half-life ASM can precipitate a cluster; drug interaction screening is essential when new medications are added |
| Illness-related | Febrile illness, urinary tract infection, gastroenteritis (vomiting ASMs), pneumonia | Fever lowers seizure threshold; vomiting/diarrhea reduces ASM absorption; systemic inflammation may promote seizure generation |
| Sleep-related | Sleep deprivation, shift work, disrupted sleep-wake cycle, obstructive sleep apnea | Sleep deprivation is one of the most potent seizure triggers; evaluation for sleep disorders should be part of epilepsy management |
| Substance-related | Alcohol use (especially binge drinking followed by withdrawal), illicit drug use (cocaine, amphetamines), marijuana cessation | Alcohol acutely raises seizure threshold but withdrawal dramatically lowers it; even moderate alcohol use in epilepsy patients increases seizure risk |
| Hormonal | Catamenial cycling (perimenstrual, periovulatory, luteal phase), peripartum period, rapid steroid taper | Estrogen is proconvulsant; progesterone (and its metabolite allopregnanolone) is anticonvulsant; the perimenstrual drop in progesterone is a common cluster trigger |
| Psychological | Emotional stress, anxiety, depression exacerbation | Stress activates the HPA axis, increasing cortisol which may promote seizure generation; stress management is an important adjunctive strategy |
| Environmental | Photosensitivity triggers (flashing lights, video games), extreme temperatures, barometric pressure changes | Relevant mainly for photosensitive epilepsies; hot environments increase seizure risk through dehydration and electrolyte disturbance |
Rescue Medications
Overview of FDA-Approved Rescue Therapies
Rescue medications for seizure clusters are rapid-acting benzodiazepines designed for non-intravenous administration by caregivers or patients in the community setting. The ideal rescue medication has rapid onset of action, ease of administration, social acceptability, and a favorable safety profile. Three formulations are FDA-approved for outpatient seizure clusters in the United States (the IM midazolam autoinjector, Seizalam, is approved for status epilepticus rather than outpatient cluster rescue):
| Product | Drug / Route | FDA Approval / Ages | Dosing | Onset / Duration | Key Features |
|---|---|---|---|---|---|
| Diastat (diazepam rectal gel) | Diazepam / Rectal | 1997 / ≥2 years | 0.2–0.5 mg/kg (rounded to available doses: 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20 mg); max 20 mg/dose; age- and weight-based; may repeat once in 4–12 hours per physician direction | Onset: 5–15 min; Duration: variable (redistribution to adipose tissue limits brain duration to 2–4 hours despite long plasma half-life) | Oldest FDA-approved rescue therapy; effective and well-studied; administration requires privacy (rectal route); absorption may be erratic; social barriers limit use in public settings |
| Valtoco (diazepam nasal spray) | Diazepam / Intranasal | 2020 / ≥6 years (expanded to ≥2 years in 2025) | Weight- and age-based: 5, 10, 15, or 20 mg (delivered as 1–2 sprays); may repeat once in 4–12 hours per physician direction; max 2 doses per episode; max 5 episodes per month | Onset: 5–15 min; Duration: similar to rectal formulation; Tmax ~1 hour (nasal) vs. ~1.5 hours (rectal) | Formulated with Intravail (DDM) absorption enhancer and vitamin E to improve nasal bioavailability of lipophilic diazepam; noninvasive; socially acceptable; can be administered regardless of body position; approved for ages ≥2 years as of 2025 |
| Nayzilam (midazolam nasal spray) | Midazolam / Intranasal | 2019 / ≥12 years | 5 mg single spray into one nostril; may repeat once in 10 minutes if seizures continue; max 2 doses per episode; max 5 episodes per month (separate by ≥3 days when possible) | Onset: ~3–5 minutes (fastest onset of non-IV formulations); Tmax ~15 minutes; Duration: 1–2 hours (shorter than diazepam) | Fastest-acting nasal formulation; midazolam is water-soluble (better nasal absorption than diazepam without special excipients); single-dose device is simple to use; shorter duration may require repeat dosing; currently approved only for ≥12 years |
| IM midazolam autoinjector | Midazolam / Intramuscular | 2018 (Seizalam) / adults — FDA-approved for status epilepticus, not outpatient seizure clusters | 10 mg IM single dose via autoinjector (thigh); single-use device | Onset: ~5–10 min; Duration: 1–2 hours | Autoinjector technology (similar to epinephrine autoinjector); no nasal administration required; useful when nasal congestion prevents intranasal use; requires injection (needle) |
Comparing Nasal Rescue Therapies
| Feature | Nayzilam (midazolam) | Valtoco (diazepam) |
|---|---|---|
| Drug | Midazolam 5 mg | Diazepam 5, 10, 15, or 20 mg |
| Approved ages | ≥12 years | ≥6 years (expanded to ≥2 years in 2025) |
| Dosing flexibility | Single fixed dose (5 mg) | Weight- and age-based dosing with multiple strengths |
| Onset of action | ~3–5 minutes (faster) | ~5–15 minutes |
| Duration of action | ~1–2 hours (shorter) | ~4–12 hours (longer, though brain concentration declines after 2–4 hours) |
| Repeat dosing | May repeat once after 10 minutes | May repeat once after 4–12 hours |
| Nasal absorption | Midazolam is water-soluble — readily absorbed without special excipients | Diazepam is lipophilic — requires Intravail (DDM) absorption enhancer |
| Effect of nasal congestion | May reduce absorption | May reduce absorption |
| Storage | Room temperature | Room temperature |
Buccal and Other Routes
- Buccal midazolam: Widely used outside the United States (Buccolam, approved in the EU for ages 3 months to 18 years); administered between the cheek and gum; effective absorption through the buccal mucosa; 10 mg dose for adults; onset similar to intranasal (~5–10 minutes); not FDA-approved in the US but commonly used off-label using the IV formulation administered buccally
- Oral benzodiazepines: Diazepam or lorazepam tablets can be taken orally if the patient is alert and able to swallow; onset is slower (30–90 minutes, jejunal absorption) and may be further delayed by recent food intake; not ideal for acute rescue but acceptable for patients who sense a pre-seizure aura with reliable prodromal warning
- Sublingual tablets: Limited data; absorption variable; not FDA-approved for seizure rescue
Practical Prescribing Considerations
- Correct dosing is essential: Insufficient doses may not stop seizure clusters, thereby increasing the risk of progression to status epilepticus; use the patient’s actual age and weight to select the appropriate dose
- Route selection: Consider patient age, setting (home vs. school vs. public), caregiver comfort, and any contraindications (nasal congestion, recent nasal surgery, rectal pathology); intranasal formulations are preferred by most patients and caregivers due to ease of use and social acceptability
- Prescribe rescue medication at the time of epilepsy diagnosis for all patients at risk for clusters; do not wait until the first cluster occurs
- Caregiver training: Provide hands-on training with demonstration devices; review administration technique at each visit; many product manufacturers offer training materials and demonstration kits
- Expiration monitoring: Ensure patients check expiration dates regularly and obtain refills before medications expire; expired benzodiazepines may have reduced potency
Seizure Action Plans
Components of a Seizure Action Plan
Providers are encouraged to discuss and develop in advance a written, individualized seizure rescue plan for each patient with epilepsy. The seizure action plan should be a clear, concise document that can be followed by any caregiver (family member, teacher, nursing staff) during a seizure emergency:
| Component | Details to Include |
|---|---|
| Patient identification | Name, date of birth, weight, photograph; epilepsy diagnosis and seizure type(s); baseline seizure frequency and typical pattern |
| Seizure description | What the patient’s typical seizures look like; how long they usually last; what recovery is expected |
| Cluster definition | Specific criteria for what constitutes a cluster for this patient (e.g., “2 or more seizures in 12 hours” or “any tonic-clonic seizure lasting >2 minutes”) |
| Immediate first aid | Keep the person safe; turn on side (recovery position); cushion the head; time the seizure; do NOT put anything in the mouth; do NOT restrain |
| Rescue medication instructions | Medication name, dose, route of administration, step-by-step instructions; when to administer (e.g., “after 2nd seizure” or “if seizure lasts >3 minutes”); whether and when to repeat |
| When to call 911 | Seizure lasting >5 minutes; seizures becoming more frequent or severe despite rescue medication; injury during seizure; respiratory difficulty or cyanosis; no return of consciousness between seizures; first-ever seizure; pregnancy |
| Emergency contacts | Neurologist/epileptologist name and number; emergency contact person; hospital preference if applicable |
| Current medications | List of all ASMs with doses; list of drug allergies; list of medications to avoid |
| Special considerations | Vagus nerve stimulator (instructions for magnet use); known seizure triggers; comorbidities (respiratory disease, cardiac conditions); do not resuscitate status if applicable |
When to Call 911 vs. Use Rescue Medication
| Scenario | Action |
|---|---|
| Known epilepsy patient; seizure cluster within typical pattern; conscious between seizures | Rescue medication at home; observe; contact neurologist if pattern worsens |
| Seizure lasts >5 minutes without stopping | Administer rescue medication AND call 911 — this meets the definition of developing status epilepticus |
| Seizures recurring with decreasing intervals; patient not recovering between seizures | Administer rescue medication AND call 911 |
| Rescue medication administered but seizures continue or worsen | Call 911; may repeat rescue medication per action plan (if within allowed dosing) |
| Injury during seizure (head trauma, aspiration, fracture) | Call 911; provide first aid; ensure airway is clear |
| Respiratory compromise: labored breathing, cyanosis, prolonged apnea | Call 911; position on side; suction if available; prepare for BLS if needed |
| First-ever seizure (no prior epilepsy diagnosis) | Call 911; emergency evaluation required for first seizure workup |
| Seizure in water (bathtub, pool) | Call 911; remove from water immediately; check breathing; initiate CPR if needed |
Safety Considerations for Rescue Benzodiazepines
- Respiratory depression: The most significant risk; however, uncontrolled status epilepticus is more likely than benzodiazepines to cause respiratory depression (demonstrated in the PHTSE trial where placebo patients had >2× the rate of respiratory dysfunction); appropriate dosing is essential
- Sedation: Expected and dose-dependent; patient should be monitored for level of consciousness and breathing after administration; recovery position (lateral decubitus) protects airway
- Underdosing: A major clinical problem — multiple studies show the majority of patients with status epilepticus are underdosed with benzodiazepines in clinical practice; underdosing reduces efficacy and may paradoxically increase the risk of progression to refractory SE
- Drug interactions: Concomitant CNS depressants (opioids, other sedatives, alcohol) increase respiratory depression risk; counsel patients about these interactions
- Chronic use: Rescue medications are intended for intermittent, episodic use; frequent use (>5 episodes per month) should prompt reassessment of baseline ASM regimen
- Nasal-specific concerns: Nasal congestion, recent nasal surgery, or active nasal bleeding may reduce intranasal drug absorption; consider alternative routes in these situations
Evidence Base for Rescue Therapies
Clinical Trial Data
The evidence supporting rescue therapies for seizure clusters has evolved significantly over the past two decades:
- Rectal diazepam (Diastat): Demonstrated efficacy in multiple randomized controlled trials since the late 1990s; reduces the number of seizures during a cluster, decreases emergency department visits, and reduces progression to status epilepticus; remains the most extensively studied rescue formulation
- Intranasal midazolam (Nayzilam): Phase 3 trials demonstrated significant reduction in seizure frequency within the treatment period compared with placebo; faster onset than rectal diazepam; 5 mg fixed dose effective across body weights in patients ≥12 years
- Intranasal diazepam (Valtoco): Bioequivalence studies demonstrated comparable pharmacokinetic profiles to rectal diazepam with more consistent absorption; post hoc analysis showed faster seizure cluster termination compared with rectal diazepam; weight-based dosing allows individualization
- IM midazolam: Supported by the RAMPART trial (status epilepticus setting) which demonstrated IM midazolam 10 mg was at least as effective as IV lorazepam 4 mg for prehospital SE treatment; autoinjector facilitates community use
Comparative Effectiveness
Key Evidence Points
- No head-to-head randomized trials directly comparing all four FDA-approved rescue formulations in the cluster seizure setting
- All FDA-approved rescue benzodiazepines are considered effective for seizure cluster termination; product selection should be guided by patient age, preference, caregiver comfort, and practical considerations
- Intranasal formulations are preferred by patients and caregivers over rectal administration due to ease of use, social acceptability, comfort, and reduced variability in absorption
- The PHTSE trial established that uncontrolled SE (placebo arm) caused more respiratory depression than benzodiazepine treatment — this principle supports early and adequate dosing of rescue medications for cluster seizures to prevent SE
- Post hoc analyses suggest that earlier administration of rescue medication during a cluster is associated with faster termination and fewer total seizures
Special Populations
Pediatric Patients
- Seizure clusters are common in pediatric epilepsy, particularly in epileptic encephalopathies (Dravet syndrome, Lennox-Gastaut syndrome)
- Approved formulations: Rectal diazepam (≥2 years), intranasal diazepam (≥2 years as of 2025 expansion), intranasal midazolam (≥12 years only)
- Weight-based dosing is essential in children; rectal diazepam dose is 0.2–0.5 mg/kg; intranasal diazepam has specific dose tiers by age and weight
- School-based seizure action plans must include authorization for school nurses or designated personnel to administer rescue medication
- Buccal midazolam (off-label in the US; approved in the EU as Buccolam for ages 3 months to 18 years) is commonly used in pediatric practice
Elderly Patients
- Increased sensitivity to benzodiazepine sedation and respiratory depression; use lower doses when possible
- Drug interactions with polypharmacy (opioids, sedatives, antihypertensives) may increase risk of CNS depression
- Fall risk after benzodiazepine administration; caregiver should ensure patient is in a safe position
- Intranasal formulations may be preferred due to ease of administration for elderly caregivers (spouse)
Patients with Intellectual Disability
- May not be able to report aura or prodromal symptoms; caregiver recognition of cluster onset is essential
- Behavioral changes may be the earliest sign of seizure clustering
- Group home and residential care staff require training on seizure recognition and rescue medication administration
- Standing orders from the prescribing neurologist facilitate timely administration in institutional settings
Optimizing Cluster Seizure Management
Beyond Rescue Medication
While rescue medication is the cornerstone of acute cluster management, a comprehensive approach includes prevention, monitoring, and baseline ASM optimization:
- Baseline ASM optimization: Frequent clusters should prompt reassessment of the maintenance ASM regimen; consider dose adjustments, drug level monitoring, addition of a second or third ASM, or referral to an epilepsy specialist
- Trigger avoidance: Identify and address modifiable triggers (medication adherence, sleep hygiene, alcohol cessation, stress management); catamenial seizure clustering may respond to supplemental progesterone or acetazolamide
- Vagus nerve stimulation (VNS): The magnet activation feature of VNS provides on-demand stimulation that may abort or shorten seizures; can be used in conjunction with rescue medication
- Responsive neurostimulation (RNS): Detects electrographic seizure activity and delivers targeted stimulation to abort seizures before they become clinically manifest; may reduce cluster frequency
- Emergency medication dose adjustments: Some clinicians provide instructions for temporary oral ASM dose increases (e.g., additional clobazam 5–10 mg for 24–48 hours) during clusters, in addition to benzodiazepine rescue therapy
Seizure Cluster Management Checklist
- Prescribe rescue medication to every patient with epilepsy at risk for clusters
- Select the rescue formulation based on patient age, preference, and practical considerations
- Provide a written seizure action plan and review it at every clinic visit
- Train patients and caregivers on rescue medication administration technique (hands-on with demonstration devices)
- Ensure rescue medication is accessible at home, school, work, and during travel
- Review rescue medication expiration dates at each visit
- Document when rescue medication is used and reassess baseline ASM if rescue use becomes frequent (>1–2 episodes per month)
- Refer to an epilepsy specialist if clusters are frequent, severe, or not responding to rescue therapy
Cluster Seizures as First Presentation
When a patient presents with a seizure cluster as their first-ever seizure, the clinical significance is heightened. A large population-based study found that patients who had a seizure cluster as their presenting seizure were at a substantially increased risk of death over subsequent years, with an overall hazard ratio of 3.06 for mortality in the years after a first seizure (equivalent to approximately 10 years of potential life lost). These patients require urgent evaluation including brain MRI, EEG, and consideration of immediate ASM treatment.
References
- Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults. Epilepsy Curr 2016;16(1):48–61.
- Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus (RAMPART). N Engl J Med 2012;366(7):591–600.
- Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001;345(9):631–637.
- Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol 2015;28(2):143–150.
- Detyniecki K, Van Ess PJ, Bhatt AB, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters — a randomized, double-blind, placebo-controlled trial. Epilepsia 2019;60(3):507–514.
- Wheless JW, Meng TC, LeClair G, et al. Diazepam nasal spray for the treatment of acute seizure clusters: pharmacokinetic and efficacy analysis. Epilepsy Res 2021;175:106694.
- Bautista RE, Gonzalez W, Jain D. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res 2011;95(1–2):158–167.
- Pang T, Ding D, Wang J, et al. Outcome following first unprovoked seizure in adults: a population-based study. Epilepsia 2024;65(1):e12–e23.
- Benbadis SR, Berkovic SF, Cascino GD, et al. Seizure clusters: recognition and treatment. Epilepsia Open 2022;7(Suppl 1):S67–S78.
- Epilepsy Foundation. Seizure Rescue Medicines. Available at: https://www.epilepsy.com/treatment/seizure-rescue-therapies. Accessed February 2026.
- Bauer S, Willems LM, Paule E, et al. The efficacy of lacosamide as secondary antiseizure medication in patients with seizure clusters: a multicenter retrospective study. Epilepsia 2023;64(5):1277–1285.
- Haut SR, Shinnar S, Moshé SL. Seizure clustering: risks and outcomes. Epilepsia 2005;46(1):146–149.